Advisory Services Network LLC Has $765,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

Advisory Services Network LLC cut its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 31.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,894 shares of the medical research company's stock after selling 1,767 shares during the period. Advisory Services Network LLC's holdings in IQVIA were worth $765,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at $33,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. lifted its holdings in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares in the last quarter. Versant Capital Management Inc lifted its stake in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after acquiring an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in IQVIA during the 4th quarter worth about $60,000. Institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

IQV has been the topic of a number of analyst reports. JPMorgan Chase & Co. cut their price target on IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. Stephens began coverage on IQVIA in a research note on Friday, December 20th. They issued an "overweight" rating and a $250.00 price target for the company. Barclays reiterated an "equal weight" rating and issued a $170.00 target price (down from $235.00) on shares of IQVIA in a report on Thursday, April 10th. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Finally, Robert W. Baird cut their price objective on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, IQVIA presently has a consensus rating of "Moderate Buy" and an average target price of $241.50.

IQVIA Stock Performance

NYSE IQV traded down $4.78 on Friday, hitting $143.66. 3,302,597 shares of the stock were exchanged, compared to its average volume of 1,403,069. The business's fifty day moving average is $177.57 and its 200 day moving average is $197.47. IQVIA Holdings Inc. has a 52 week low of $135.97 and a 52 week high of $252.88. The company has a market capitalization of $25.33 billion, a PE ratio of 19.15, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.